ArcticZymes Technologies Q4 and full year 2022 results

02 Feb 2023 07:00 CET

Tromsø, Norway, 2[th] February 2022 - ArcticZymes Technologies (OSE: AZT)
reported sales of NOK 28.2 million (40.5) and an EBITDA of NOK 1.3 million
(20.8) for the fourth quarter of 2022.

Highlights from Q4 and the full year 2022

· ArcticZymes Technologies (AZT) had Q4 sales of NOK 28.2 million a reduction
of 30% (Q4 2021: NOK 40.5 million) and sales for the full year of NOK 137.0
million growing by 7% (12M 2021: NOK 128.0 million)
· AZT had a positive EBITDA for Q4 of NOK 1.3 million, a reduction of NOK 19.5
million (Q4 2021: NOK 20.8 million) and a positive EBITDA for 2022 of NOK 41.5
million, a reduction of 20.1 million (12M 2021: NOK 61.6 million).
· Operating expenses for Q4 were 26.0 million (Q4 2021: NOK 18.4 million)
impacted by one-off expenditure. Operating expenses for 2022 totalled NOK 91.0
(12M 2021: NOK 65.5 million)
· Cash flow for Q4 was positive NOK 5.6 million (Q4 2021: NOK 14.0 million)
giving a cash balance of NOK 244.2 million (Q4 2021: NOK 200.4 million)
· Launched 3 new products: AZscript[TM] Reverse Transcriptase; SAN HQ 2.0
ELISA kit & ArcticZymes Proteinase Glycerol FREE
· Upscaled the manufacturing capacity of AZ Proteinase to meet growing demand
· Signed exclusive license deal for a novel DNA assembly technology to expand
offerings in both the molecular tools and biomanufacturing businesses
· Conducted a comprehensive M&A process and engaged in negotiations with a
European company. As a result of due diligence findings however, AZT terminated
the acquisition process

-Ends-

Presentation and Webcast

The Company will host a Q4 2022 presentation, followed by an extended investor
presentation for investors, analysts and media at 08:30 CET on Thursday, 02
February 2023 at Høyres Hus, Stortingsgata 20, Oslo.

The presentation will be given by the Chairman of the board, Marie Roskrow, CFO,
Børge Sørvoll, VP Business Development and Marketing, Dirk Hahneiser, VP of
Operations, Marit Sjo Lorentzen and CSO, Darren Ellis. CEO, Jethro Holter is
currently on sick leave and will not participate.

The presentation can also be followed as a live webcast from Hegnar TV on
www.arcticzymes.com or
https://channel.royalcast.com/landingpage/hegnarmedia/20230202_2/. It will be
possible to post questions through the webcast console.

The result, report and presentation for the fourth quarter 2022 and the extended
investor presentation will be available on www.newsweb.no and on the company's
homepage www.arcticzymes.com from 07.00 CET on Thursday, 02. February 2023.

For more information, please contact:

ArcticZymes Technologies ASA
Chairman of the Board, Marie Roskrow Tel: +44 (0) 74 96 959743
CFO, Børge Sørvoll Tel: +47 95 29 01 87
ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 as ArcticZymes Technologies under
the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA
Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.

More information:
Access the news on Oslo Bors NewsWeb site

581190_AZT_Q4_2022_Report.pdf
581190_AZT_Q4_2022_Press_release_1.pdf